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EFFECT OF PATIENT EDUCATION AND SUPERVISED
EXERCISE IN PATIENTS WITH HIP OSTEOARTHRITIS.
A RANDOMIZED CLINICAL TRIAL
L. Fernandes1, K. Storheim1, L. Nordsletten2, M. Risberg1
1NAR, Orthopaedic Ctr., Oslo Univ. Hosp., Ullevaal, Oslo, Norway;
2Orthopaedic Ctr., Oslo Univ. Hosp., Ullevaal, Oslo, Norway
Purpose: The purpose of the study was to evaluate the effect of
a supervised exercise program in addition to patient education for
patients with hip osteoarthritis.
Methods: One hundred and nine patients were included and
received three sessions of patient education. After completing
the patient education the 109 patients were randomized into 1)
follow the recommendations of self-management given during the
patient education (CG), or 2) follow the recommendations and,
in addition, a supervised exercise program (EG). The intervention
period lasted for 14 weeks. The patients were followed-up at
post-intervention (FU0), six months post-intervention (FU6), and
one year post-intervention (FU12). The main outcome was the
WOMAC VA3.1, and secondary outcomes were the 36-item Short-
Form health related quality of life questionnaire (SF-36v2), the
modiﬁed Physical Activity Scale for the Elderly (PASE) and the
self-efﬁcacy for pain. Linear mixed models analyses were used
for between group differences over time, and standardized mean
difference for the calculation of effect sizes.
Results: WOMAC physical function showed a signiﬁcant improved
score for the EG compared to the CG (p=0.047, CI 0.6-11.0) over
the follow-up period. No signiﬁcant differences between groups
over the follow-up period were seen for WOMAC pain or stiffness
subscales. Within-group analysis for the EG showed signiﬁcantly
improved WOMAC pain from baseline to FU0 (p=0.025, CI 0.7-
9.7), FU6 (p=0.004, CI 2.5-12.5), and FU12 (p=0.021, CI 0.8-10.1).
There were no signiﬁcant changes over time for the CG. The effect
sizes for the EG compared to the CG ranged from 0.26-0.35,
0.16-0.46, and 0.48-0.58 for pain, stiffness and physical function,
respectively, over the follow-up period. The secondary outcome,
SF-36 bodily pain, showed signiﬁcantly improved score (p=0.009,
CI 2.2-15.5) for the EG over the follow-up period. No signiﬁcant
differences between groups were seen in any of the other SF-36
sub-scales, in activity level (PASE) or in self-efﬁcacy for pain over
the follow-up period.
Conclusions: Physical function (WOMAC) and bodily pain (SF-
36) was signiﬁcantly improved for the EG compared to the CG
over the 1 year follow-up period, but there were no signiﬁcant
differences between the two groups for other WOMAC or SF-36
sub-scales, physical activity level or self-efﬁcacy for pain. There
was a small to moderate effect size for pain, stiffness, and physical
function for the EG compared to the CG.
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ALLOGENIC CHONDROCYTES: A 2-YEAR FOLLOW-UP
A.A. Dhollander, K.F. Almqvist, P.C. Verdonk, R. Forsyth,
R. Verdonk, G. Verbruggen
Ghent Univ., Ghent, Belgium
Purpose: To determine whether the implantation of alginate beads
containing human mature allogenic chondrocytes is feasible and
safe for the treatment of symptomatic cartilage defects in the knee.
Methods: A biodegradable, alginate-based biocompatible scaf-
fold containing human mature allogenic chondrocytes was used
for the treatment of chondral and osteochondral lesions in the
knee. Twenty-one patients were clinically prospectively evaluated
with use of the Western Ontario and McMaster Universities Os-
teoarthritis Index (WOMAC) and a Visual Analogue Scale (VAS)
for pain preoperatively and at 3, 6, 9, 12, 18 and 24 months of
follow-up. Of the 21 patients, 13 had consented to the taking of
a biopsy for investigative purposes from the area of implantation
at 12 months of follow-up, allowing histological assessment of the
repair tissue.
Results: A statistically signiﬁcant clinical improvement became
apparent after 6 months and patients improved during the 24
months of follow-up. Adverse reactions to the alginate/ﬁbrin matrix
seeded with the allogenic cartilage cells were not observed. Histo-
logical analysis of the biopsy specimens rated the repair tissue as
hyaline-like in 15.3 %, as mixed tissue in 46.2 %, as ﬁbrocartilage
in 30.8% and as ﬁbrous in 7.7%.
Conclusions: The results of this short term pilot study show that
the alginate-based scaffold containing human mature allogenic
chondrocytes is feasible and safe for the treatment of symptomatic
cartilage defects of the knee. The described technique provides
clinical and histological outcomes equal but not superior to those
of other cartilage repair techniques.
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THE EFFECTIVENESS OF GLUCOSAMINE SULFATE ON
CHRONIC LOW BACK PAIN WITH DEGENERATIVE
CHANGES. A RANDOMIZED TRIAL.
P. Wilkens Jr., K. Storheim, O. Grundnes, C. Hellum, I. Scheel
Ulleval Univ. Hosp., Oslo, Norway
Purpose: The aim of this trial is to test whether glucosamine
sulfate (GS) can reduce pain and discomfort in patients with
chronic low back pain LBP) and MRI-conﬁrmed degenerative
changes. Systematic reviews have reported potential mild effects
of glucosamine on knee osteoarthritis (OA), although the scientiﬁc
quality has been criticized. Though a clear relationship between
LBP and lumbar degenerative changes has not been found, GS
is increasingly being used in treatment. We have been unable to
identify any high quality trials on the effect of GS on chronic LBP.
A study of the effect of GS on chronic LBP is therefore needed.
Methods: The study is a randomized, double-blind, placebo-
controlled trial. Patients were recruited through primary health per-
sonnel and a single newspaper advert. Inclusion criteria: primary
complaint of chronic LBP (more than 6 months), ﬁndings of lumbar
degeneration seen on lumbar MRI (e.g. Modic changes, reduced
disc height etc), >25 years, able to speak and read Norwegian and
written informed consent. Exclusion criteria: symptomatic prolapse
and spinal stenosis, previous lumbar fracture or surgery, preg-
nancy, breastfeeding, seafood allergy or other disorders (physical
and/or psychological) known to inﬂuence their LBP. Interventions:
Patients were randomized (concealed and computer-generated)
to receive 1500mg GS (from Pharma Nord) daily or placebo. Out-
comes were measured 6, 12 and 24 weeks. Primary outcome: A 3
point difference in reduction between glucosamine- and placebo-
group measured with the Roland Morris Disability Questionnaire
(RMDQ). RMDQ is a self-reported measurement of pain and dis-
ability related to LBP. The properties of RMDQ have been studied
extensively. Secondary outcomes: Numerical Rating Scale (NRS)
for LBP and leg pain when active and inactive; low back stiff-
ness measured by NRS; health related quality of life (EQ-5D);
plasma glucose and cholesterol measured pre and post study
participation. Statistical analysis: Parametrical or non-parametrical
tests (e.g. indepentent t-tests, ANOVA analysis) will be used in
the main analysis depending on the data distribution. SPSS will
be used to conduct the analysis and followed the intention to treat
principle. The interim analysis reported here utilized repeated
